Drugs / AMC6156
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07072195 | Jul 2025 → Mar 2026 overdue | myopathy, pelvic muscle wasting | Animuscure Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMC6156 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07072195 ↗ |
| Route | Oral | “Oral administration of AMC6156 in tablet form at a dose of 0.1 mg once daily for 12 weeks.” NCT07072195 ↗ |